1. Real-Life Analysis of Efficacy and Safety of Everolimus Plus Exemestane in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Negative Metastatic Breast Cancer Patients: A Turkish Oncology Group (TOG) Study.
- Author
-
Bilici A, Uysal M, Menekse S, Akin S, Yildiz F, Turan M, Sezgin Goksu S, Beypinar I, Sakalar T, Değirmenci M, Erdem D, Basaran G, Olmez OF, Avci N, Tural D, Sakin A, Turker S, Demir A, Temiz S, Kaplan MA, Dogan M, Tanriverdi O, Bilgetekin I, Cinkir HY, Acikgoz O, Paydas S, Uslu R, and Turhal S
- Subjects
- Adult, Aged, Aged, 80 and over, Androstadienes therapeutic use, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Breast Neoplasms metabolism, Everolimus therapeutic use, Female, Humans, Middle Aged, Neoplasm Metastasis, Receptor, ErbB-2 metabolism, Receptors, Estrogen metabolism, Receptors, Progesterone metabolism, Retrospective Studies, Survival Analysis, Treatment Outcome, Turkey, Androstadienes administration & dosage, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Breast Neoplasms drug therapy, Everolimus administration & dosage
- Abstract
Purpose: This study evaluated the efficacy and safety of everolimus (EVE) plus exemestane (EXE) in hormone-receptor positive (HR+), human epidermal growth factor receptor-2-negative (HER2-) metastatic breast cancer (MBC) patients in real-life settings., Methods: Overall, 204 HR+, HER2- MBC patients treated with EVE + EXE after progressing following prior endocrine treatment were included. Overall survival (OS) and progression-free survival (PFS) and safety data were analyzed., Results: The objective response rate, median PFS, and median OS were 33.4%, 8.9 months, and 23.4 months, respectively. Multivariate analysis revealed that negative progesterone receptor status was a significant determinant of poor treatment response ( p = 0.035) and PFS ( p = 0.024). The presence of bone-only metastasis was associated with better treatment response ( p = 0.002), PFS ( p < 0.001), and OS ( p = 0.001)., Conclusion: We confirmed the favorable efficacy and safety profile of EVE + EXE for HR+, HER - MBC patients.
- Published
- 2022
- Full Text
- View/download PDF